STAT's Morning Rounds newsletter, in an October 14, 2026, item by addiction reporter Theresa Gaffney, reported that a newly announced trial will test weekly semaglutide injections in people with substance use disorders [1]. The study will examine real-world outcomes, including participants' involvement with the criminal justice system, employment, housing stability and health care utilization [1]. It is set to begin in early 2027 and will enroll up to 1,200 participants with alcohol use disorder, opioid use disorder, or both [1].
What is planned
The trial is a collaboration between the Center for Addiction Science, Policy and Research, a nonprofit focused on GLP-1 drugs for addiction treatment, and the Allegheny County Department of Human Services in Pennsylvania [1]. Researchers plan to track participant outcomes using the county's linked administrative data [1]. STAT places the study within a wave of clinical trials testing GLP-1 weight loss drugs, the class that includes semaglutide, against various substance use disorders, and describes some of those results as promising [1]. The newsletter does not name those earlier trials or report their findings [1].
Why it matters to readers here
For adults who use or are considering a GLP-1 medicine for weight management, the story describes research on this drug class extending from weight loss to substance use disorders, and now to outcomes such as employment and housing [1]. Gaffney called it "a large, major study" and noted that a strong connection, if found, could support arguments for greater public spending on the medication [1].
The same newsletter also linked to an NPR report on ongoing lawsuits alleging that GLP-1 drugs can cause serious harm, with a headline noting that how often such harm occurs is not known [1]. The trial announcement therefore appeared alongside a report on unresolved safety questions about the same drug class [1].
What to watch next
- Whether a public protocol describes the trial's design, including whether participants are randomized, what the comparison group receives, which outcome is primary and how long follow-up lasts, none of which STAT reports [1].
- Whether enrollment starts on the early-2027 schedule and approaches the planned ceiling of 1,200 participants [1].
- How the county's linked administrative data are used to measure justice, employment, housing and health care utilization outcomes [1].
- Published results from the earlier GLP-1 trials in substance use disorders that STAT says are already under way [1].
What the report does not say
The source is a short newsletter item rather than a study report or trial registration, and it gives no dose amount, eligibility criteria beyond the two diagnoses, funding details or timeline for results [1]. It does not state whether participants will receive other addiction treatment alongside semaglutide [1]. The item reports an announced trial, not findings, and offers no data on what semaglutide does for people with alcohol or opioid use disorder [1].
References
- statnews.com. New study examines GLP-1 impact on interactions with criminal justice system, employment, housing stability. Accessed October 14, 2026. https://www.statnews.com/2026/10/14/health-news-glp-1-study-impact-interactions-with-criminal-justice-system-employment/